(2R,4S)-methyl 4-amino-1-(3,4-dichlorophenylsulfonyl)pyrrolidine-2-carboxylate | 1408186-58-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2R,4S)-methyl 4-amino-1-(3,4-dichlorophenylsulfonyl)pyrrolidine-2-carboxylate
• 英文别名: methyl (2R,4S)-4-amino-1-(3,4-dichlorophenylsulfonyl)pyrrolidine-2-carboxylate；methyl (2R,4S)-4-amino-1-(3,4-dichlorophenyl)sulfonylpyrrolidine-2-carboxylate
• CAS: 1408186-58-2
• 化学式: C₁₂H₁₄Cl₂N₂O₄S
• 分子量: 353.226
• InChiKey: GEVIJSRZAJXFKH-WRWORJQWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  98.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (2R,4S)-methyl 4-amino-1-(3,4-dichlorophenylsulfonyl)pyrrolidine-2-carboxylate 在 盐酸羟胺 、 三乙胺 、 potassium hydroxide 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 72.0h， 生成 (2R,4S)-1-(3,4-dichlorophenyl)sulfonyl-N-hydroxy-4-(thiophene-2-carbonylamino)pyrrolidine-2-carboxamide
  参考文献：
  名称：

  d-Proline-based peptidomimetic inhibitors of anthrax lethal factor

  摘要：

  In this work we reported the generation of D-proline-derived hydroxamic acids as inhibitors of anthrax lethal factor (LF), taking advantage of a pyrrolidine ring as the central scaffold and a hydroxamate group as the Zn2+ chelating agent. The introduction of two hydrophobic groups addressing the S1' subsite and a long substrate-binding groove was conceived by overlapping the bioactive conformations of two reported LF inhibitors. Micromolar affinity of compound 38 suggested cis-3-substituted-1-sulfonamido-D-proline hydroxamic acids as a promising class of peptidomimetic inhibitors for developing novel LF inhibitors. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.08.028
• 作为产物：
  描述：

  顺式-4-羟基-D-脯氨酸甲酯 在 4-二甲氨基吡啶 、 sodium azide 、 palladium 10% on activated carbon 、 氢气 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 (2R,4S)-methyl 4-amino-1-(3,4-dichlorophenylsulfonyl)pyrrolidine-2-carboxylate
  参考文献：
  名称：

  d-Proline-based peptidomimetic inhibitors of anthrax lethal factor

  摘要：

  In this work we reported the generation of D-proline-derived hydroxamic acids as inhibitors of anthrax lethal factor (LF), taking advantage of a pyrrolidine ring as the central scaffold and a hydroxamate group as the Zn2+ chelating agent. The introduction of two hydrophobic groups addressing the S1' subsite and a long substrate-binding groove was conceived by overlapping the bioactive conformations of two reported LF inhibitors. Micromolar affinity of compound 38 suggested cis-3-substituted-1-sulfonamido-D-proline hydroxamic acids as a promising class of peptidomimetic inhibitors for developing novel LF inhibitors. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.08.028

文献信息

• A study of a<scp>d</scp>-proline peptidomimetic inhibitor of melanoma and endothelial cell invasion through activity towards MMP-2 and MMP-9
  作者：Francesca Bianchini、Chiara Calugi、Jessica Ruzzolini、Gloria Menchi、Lido Calorini、Antonio Guarna、Andrea Trabocchi

  DOI：10.1039/c4md00287c

  日期：——

  Ad-proline peptidomimetic targeting MMP-2 and MMP-9 was identified from a pool of compounds following enzyme inhibition kinetics and Matrigel sponge assays, showing the capacity of blocking capillary network formationin vivo.

  从一组化合物中，通过酶抑制动力学和Matrigel海绵实验鉴定出一种靶向MMP-2和MMP-9的Ad-脯氨酸肽类拟态物，显示其在体内阻断毛细血管网络形成的能力。
• d-Proline-based peptidomimetic inhibitors of anthrax lethal factor
  作者：Chiara Calugi、Andrea Trabocchi、Claudia Lalli、Antonio Guarna

  DOI：10.1016/j.ejmech.2012.08.028

  日期：2012.10

  In this work we reported the generation of D-proline-derived hydroxamic acids as inhibitors of anthrax lethal factor (LF), taking advantage of a pyrrolidine ring as the central scaffold and a hydroxamate group as the Zn2+ chelating agent. The introduction of two hydrophobic groups addressing the S1' subsite and a long substrate-binding groove was conceived by overlapping the bioactive conformations of two reported LF inhibitors. Micromolar affinity of compound 38 suggested cis-3-substituted-1-sulfonamido-D-proline hydroxamic acids as a promising class of peptidomimetic inhibitors for developing novel LF inhibitors. (C) 2012 Elsevier Masson SAS. All rights reserved.